In August 2024, Bharat Biotech International Ltd launched Hillchol, a novel single-strain oral vaccine for which disease? 

The correct answer is Cholera.

Key Points

• Hillchol is a single-strain oral cholera vaccine developed by Bharat Biotech International Ltd.
• It was launched in August 2024 to address cholera outbreaks.
• The vaccine is designed to provide long-term immunity against cholera.
• Hillchol is significant in preventing cholera in endemic regions and during outbreaks.
• Bharat Biotech has a history of developing vaccines for various diseases, enhancing their reputation in the pharmaceutical industry.

Additional Information

• Cholera
  • Cholera is an acute diarrheal illness caused by infection with the bacterium Vibrio cholerae.
  • It is often spread through contaminated water and food, especially in areas with inadequate sanitation.
  • Symptoms include severe watery diarrhea, which can lead to dehydration and even death if untreated.
  • Effective treatment includes oral rehydration solutions and, in severe cases, intravenous fluids and antibiotics.
  • Preventive measures include improved sanitation, clean water, and vaccination.
• Vaccine Development
  • Vaccine development involves several phases including exploratory, preclinical, clinical development, regulatory review, and manufacturing.
  • Oral vaccines are particularly beneficial for diseases like cholera due to ease of administration and acceptance.
  • Single-strain vaccines target a specific strain of a pathogen, providing focused immunity.
  • Rigorous testing ensures the safety and efficacy of vaccines before they are approved for public use.
• Bharat Biotech International Ltd
  • Bharat Biotech is an Indian biotechnology company known for developing vaccines and biotherapeutics.
  • Founded in 1996, it has developed vaccines for diseases such as rotavirus, hepatitis, and COVID-19.
  • The company focuses on innovative research and development to address public health challenges.
  • It collaborates with global health organizations to enhance vaccine accessibility in developing countries.